Mutant HRAS as novel target for MEK and mTOR inhibitors
Michael K. Kießling(German Cancer Research Center), Gerhard Rogler(University of Regensburg)
Cited by 59
Related Papers
Extraintestinal Manifestations of Inflammatory Bowel Disease
|Inflammatory Bowel Diseases|2015|891
Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome
|Gut|2016|318
Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohnʼs disease
|Inflammatory Bowel Diseases|2008|143